Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

• Published in: British journal of dermatology (1951) Vol. 172; no. 2; pp. 484 - 493
• Main Authors: Blauvelt, A., Prinz, J.C., Gottlieb, A.B., Kingo, K., Sofen, H., Ruer-Mulard, M., Singh, V., Pathan, R., Papavassilis, C., Cooper, S.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.02.2015
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections; Male; Middle Aged; Patient Satisfaction; Psoriasis - drug therapy; Self Administration; Syringes; Treatment Outcome; Young Adult

Summary Background Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, demonstrated efficacy and safety in moderate‐to‐severe plaque psoriasis when administered via subcutaneous injection. Self‐administration by pre‐filled syringe (PFS) can offer patients clinical benefits of a drug...